Back to Search Results
Study Complete
Sponsor ID
HPN-100-009

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age with Urea Cycle Disorders

Sponsor ID
HPN-100-009
Clinicaltrials.gov ID
NCT02246218
EUCTIS ID
N/A
EudraCT ID
2016-003460-38
Contact Us

Study Details

This is an open-label study consisting of a transition period to RAVICTI, followed by a safety extension period for at least 6 months and up to 24 months of treatment with RAVICTI, depending on age at enrollment. It is designed to capture information important for evaluating safety, pharmacokinetics and efficacy in young children.

Subjects who are followed by or referred to the Investigator for management of their UCD. Subjects eligible for this study will include patients ranging from newborn to < 2 years of age with either a diagnosed or clinically suspected UCD.

Additional Study Details

Phase
Phase 4
Product
N/A
Type
Interventional
Masking
None (Open Label)
Enrollment
27
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

Location
Status
Contact Us
Location
Maine Medical Center
Portland, ME, United States, 04102
Status
Completed
Location
University of Minnesota
Minneapolis, MN, United States, 55455
Status
Completed
Location
Children's National Medical Center
Washington, DC, United States, 20010
Status
Completed
Location
Children's Hospital of Pittsburgh
Pittsburgh, PA, United States, 15224
Status
Completed
Location
University Hospitals Case Medical Center
Cleveland, OH, United States, 44106
Status
Completed
Location
Mount Sinai School of Medicine
New York, NY, United States, 10029
Status
Completed
Showing {first} - {last} of {total} Results
Study Info
Age
1 Days - 2 Years
Condition
  • Urea Cycle Disorder
    • Sex
    All
    Trial Dates
    Dec 2014 - Oct 2016
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Male and female subjects up to 2 years of age - Signed informed consent by subject's parent/legal guardian - UCD diagnosis or suspected diagnosis of any subtype, except N-acetyl glutamate synthetase deficiency. If UCD has not been previously confirmed by genetic testing, consent must be obtained from parent/legal guardian prior to perform genetic testing. If genetic testing is inconsistent with or excludes a UCD diagnosis, the subject will be withdrawn from the study.
    Exclusion Criteria:
    - Use of any investigational drug within 30 days of Day 1 - Uncontrolled infection (viral or bacterial) or any other condition known to precipitate hyperammonemic crises. Once these precipitating factors are medically controlled, patients presenting in crisis are eligible. - Any clinical or laboratory abnormality of Grade 3 or greater severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03, except Grade 3 elevations in ammonia and liver enzymes, defined as levels 5-20 times the upper limit of normal in alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyl transpeptidase (GGT) in a clinically stable subject - Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the subject at increased risk by participating in this study - Known hypersensitivity to phenylacetate (PAA) or phenylbutyrate (PBA) - Liver transplantation, including hepatocellular transplant - Subjects on hemodialysis at time of initiating RAVICTI - Subjects on RAVICTI for UCD management - Currently treated with Carbaglu® (carglumic acid)